Advertisement

Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer

The investigators review the efficacy results from dual HER-2 blockade studies and present new post hoc analysis efficacy data according to HR status.

 Clinical Breast Cancer